BACKGROUND There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: unconjugated and radio-labeled Abs. METHODS The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article. DISCUSSION Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.

中文翻译：

---

针对 CD20 的 MAb 的治疗用途

背景 有两大类针对 CD20 Ag 的抗体已被开发用于治疗目的：未结合的和放射性标记的抗体。方法 本文总结了使用未结合和放射性标记的抗体的大型临床试验的临床结果。讨论 这两类药物在单独和与常规化疗或大剂量化疗和移植联合使用的临床试验中都显示出前景。对这些药物的持续研究将为这些药物在临床实践中的地位提供进一步的证据。